arrow_back Back Filing freshness 10-Q Q1 FY2027 SEC EDGAR

HAEMONETICS CORP

HAE
$124.11 ▼ -3.28 (-2.57%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
71 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
65
Health
Fair
Bearish
auto_awesome

Analytical Summary

HAEMONETICS CORP faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $5.6B
Dividend Yield —
Revenue Growth 5.6% ↗
Op. Margin 16.9% ↗
ROIC 2.0% ↗
FCF / Share $0.98
Trailing P/E 170.0x
Price / Book 6.7x
FCF Yield 0.8%
Debt / Equity 1.42
info Valuation on last close. End-of-day price, Nov 5, 2026.

71-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$339.38M
↑ +5.6% —
Net Income Profit after all expenses
$33.01M
↓ -3.0% —
Operating Margin Operating profit as % of sales
16.9%
↑ +354.7% 69th
FCF / Share Free cash flow per share
$0.98
↑ +245.4% —
Long-Term Debt Long-term obligations
$1.19B
↓ -4.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability ↑
69
Returns ↑
67
Financial Health →
45
Cash Quality ↑
90

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 19 years · 71 quarters